Pages that link to "Q39122553"
Jump to navigation
Jump to search
The following pages link to Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells (Q39122553):
Displaying 50 items.
- Adoptive immunotherapy against ovarian cancer (Q26748905) (← links)
- Chimeric antigen receptor T-cell therapy for solid tumors (Q26750908) (← links)
- Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy (Q26752955) (← links)
- Metabolic communication in tumors: a new layer of immunoregulation for immune evasion (Q26765256) (← links)
- Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy (Q26773309) (← links)
- Novel immunotherapies in lymphoid malignancies (Q26777394) (← links)
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors (Q26778759) (← links)
- Adoptive T-Cell Immunotherapy (Q26782845) (← links)
- Relevance of tumor-infiltrating lymphocytes in breast cancer (Q26795598) (← links)
- Adoptive T-cell therapy for cancer: The era of engineered T cells (Q26800611) (← links)
- CAR T Cell Therapy: A Game Changer in Cancer Treatment (Q26822769) (← links)
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications (Q26996518) (← links)
- Adoptive cell therapy for sarcoma (Q27009541) (← links)
- Genetically modified T cells in cancer therapy: opportunities and challenges (Q27026627) (← links)
- Antigen-specific T cells fully conserve antitumour function following cryopreservation (Q27323082) (← links)
- Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy (Q28066199) (← links)
- Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination (Q28068378) (← links)
- Targeting immune checkpoints in malignant glioma (Q28072012) (← links)
- Focus on Nivolumab in NSCLC (Q28073759) (← links)
- Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment (Q28076294) (← links)
- T-cell receptor gene therapy--ready to go viral? (Q28081611) (← links)
- Smart CARs engineered for cancer immunotherapy (Q28087236) (← links)
- Expression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic Mice (Q30399332) (← links)
- Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene (Q30403182) (← links)
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment (Q33606150) (← links)
- T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth (Q33632100) (← links)
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells (Q33671867) (← links)
- In Vivo Murine-Matured Human CD3+ Cells as a Preclinical Model for T Cell-Based Immunotherapies. (Q33796950) (← links)
- Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab (Q33912075) (← links)
- Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells (Q33992425) (← links)
- Rapid and efficient transfer of the T cell aging marker CD57 from glioblastoma stem cells to CAR T cells (Q34044302) (← links)
- Driving CAR T-cells forward (Q34046505) (← links)
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition (Q34047618) (← links)
- Engineered T cells for cancer therapy. (Q34080368) (← links)
- Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects (Q34256494) (← links)
- Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. (Q34487189) (← links)
- Combination cancer immunotherapy and new immunomodulatory targets (Q34487698) (← links)
- Prospects for gene-engineered T cell immunotherapy for solid cancers. (Q34507561) (← links)
- Clinical application of genetically modified T cells in cancer therapy (Q34511646) (← links)
- Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection (Q34517676) (← links)
- Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy (Q34550649) (← links)
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. (Q34809019) (← links)
- Novel immune checkpoint blocker approved for the treatment of advanced melanoma (Q34936394) (← links)
- Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment (Q35151883) (← links)
- Current advances in T-cell-based cancer immunotherapy (Q35215158) (← links)
- Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors (Q35689938) (← links)
- Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs (Q35757397) (← links)
- Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T (Q35798161) (← links)
- Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer (Q35980893) (← links)
- Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy (Q36173500) (← links)